A gene-silencing drug offers hope for children with a rare epilepsy

Some children are born with a faulty SCN2A gene that causes relentless seizures and steals their development. Praxis's elsunersen is designed to quiet just that faulty gene's messages. The FDA granted it breakthrough status, speeding its path to the children who need it.